{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"To evaluate pharmacogenomic markers among patients with treatment related polyneuropathy.","groups":[{"description":"Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age)\n\nConsolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15\n\nLenalidomide\n\nBortezomib\n\nDexamethasone","id":"OG000","title":"Treatment Arm"}],"populationDescription":"No pharmacogenomic markers were evaluated for relation to neuropathy","reportingStatus":"POSTED","timeFrame":"2 years","title":"Pharmacogenomic Markers of Neuropathy","type":"SECONDARY"}